A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC
Phase of Trial: Phase I/II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs AZD 4635 (Primary) ; Oleclumab (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
- 27 Aug 2018 Planned End Date changed from 14 Dec 2021 to 29 Dec 2021.
- 27 Aug 2018 Planned primary completion date changed from 14 Dec 2021 to 29 Dec 2021.